Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of photodynamic therapy with
lutetium texaphyrin in treating patients with locally recurrent prostate cancer. Photodynamic
therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor
cells. This may be effective treatment for locally recurrent prostate cancer.
Photosensitizing drugs, such as lutetium texaphyrin, are absorbed by cancer cells and, when
exposed to light, become active and kill the cancer cells